SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

Highlights Shin Nippon Biomedical Laboratories, Ltd. OTC Markets

Equities

SBLOF

JP3379950003

Market Closed - OTC Markets Other stock markets 11:58:04 2023-05-16 EDT			5-day change	1st Jan Change
16.97 ^USD	-.--%		-.--%	-.--%

07-05	Jefferies Cuts Shin Nippon Biomedical Laboratories' EPS Estimates by 37% on 'Disappointing' Guidance, Weak Translational Research Unit	MT
07-05	Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 1,500 Yen From 2,800 Yen	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jefferies Cuts Shin Nippon Biomedical Laboratories' EPS Estimates by 37% on 'Disappointing' Guidance, Weak Translational Research Unit	07-05	MT
Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025	05-07	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025	05-07	CI
Final dividend	03-27	FA
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	02-01	CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024	11-07	CI
Ex-dividend day for interim dividend	23-09-27	FA
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	23-08-01	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	23-08-01	CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting	23-06-15	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	23-06-07	CI
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-08	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	23-05-08	CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023	23-05-08	CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	23-05-08	CI
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	23-04-18	MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	23-04-17	MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	23-04-16	CI
Ex-dividend day for final dividend	23-03-29	FA
Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-01-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shin Nippon Biomedical Laboratories, Ltd. OTC Markets

Equities

SBLOF

JP3379950003

Highlights

Filters